| 國立成功大學 |
2020-12-3 |
Between-module functional connectivity of the salient ventral attention network and dorsal attention network is associated with motor inhibition
|
Hsu;Muchen, Howard;Yao;Zai-Fu;Hwang;Kai;Hsieh;Shulan |
| 國立中山大學 |
2001-06-06 |
Betwixt the Text and the Tenor: Promiscuous Liminality of English in Derek Walcott’s Poetry
|
Ting-yao Luo |
| 國立成功大學 |
2024-01-22 |
BET抑制劑在Doxorubicin治療下對心肌細胞的影響及機制
|
吳柏鴻; Wu, Po-Hung |
| 臺北醫學大學 |
2005 |
Bevacizumab (Avastin) plus Chemotherapy in the Treatment of Metastatic Colorectal Carcinoma—A Multi-institutional Experience in Taiwan
|
戴承正; Tai CJ |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立臺灣海洋大學 |
2016-03 |
Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts
|
Po-Lei Wei; Yu-Jia Chang; Chun-Chao Chang; Hung-Yi Chiou; Chang-Jer Wu; Cheng-Jeng Tai; Hang Wang; Chien-Kai Wang; Chen-Jei Tai; Ming-Te Huang; Chih-Hsiung Wu; Ray-Jade Chen; Li-Jen Kuo |
| 臺大學術典藏 |
2018-09-10T18:03:32Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh, Y.-T.;Yang, C.-M.;Chang, S.-H.; CHUNG-MAY YANG; SHU-HUI CHANG |
| 臺大學術典藏 |
2020-05-21T02:19:06Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh, Yi-Ting;Chung-May Yang;Shu-Hui Chang; Hsieh, Yi-Ting; CHUNG-MAY YANG; SHU-HUI CHANG |
| 臺大學術典藏 |
2022-05-03T06:19:24Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh Y.-T.; Yang C.-M.; SHU-HUI CHANG |
| 臺大學術典藏 |
2022-07-15T06:43:04Z |
Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema
|
Hsieh Y.-T.; CHUNG-MAY YANG; Chang S.-H. |
| 臺大學術典藏 |
2021-05-03T02:20:41Z |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
Andr? T.;Vernerey D.;Im S.A.;Bodoky G.;Buzzoni R.;Reingold S.;Rivera F.;Mckendrick J.;Scheithauer W.;Ravit G.;Fountzilas G.;Yong W.P.;Isaacs R.;?Sterlund P.;Jin-Tung Liang;Creemers G.J.;Rakez M.;Van Cutsem E.;Cunningham D.;Tabernero J.;De Gramont A.; Andr? T.; Vernerey D.; Im S.A.; Bodoky G.; Buzzoni R.; Reingold S.; Rivera F.; McKendrick J.; Scheithauer W.; Ravit G.; Fountzilas G.; Yong W.P.; Isaacs R.; ?sterlund P.; JIN-TUNG LIANG; Creemers G.J.; Rakez M.; Van Cutsem E.; Cunningham D.; Tabernero J.; de Gramont A. |
| 臺大學術典藏 |
2020-01-22T07:50:23Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Chiang Y.-C.; CHI-AN CHEN; Cheng W.-F.; Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chi-An Chen;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L. |
| 臺大學術典藏 |
2020-02-06T05:21:47Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG; WEN-FANG CHENG;Chen C.-A.;Chiang Y.-C.;Chen Y.-L.;Tai Y.-J.;Hsu H.-C.;Lee S.-P.; Lee S.-P. |
| 臺大學術典藏 |
2020-02-14T02:49:36Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Wen-Fang Cheng; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; WEN-FANG CHENG |
| 臺大學術典藏 |
2020-02-14T08:50:30Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P; Hsu H.-C; Tai Y.-J; Chen Y.-L; YING-CHENG CHIANG; Chen C.-A; Cheng W.-F. |
| 臺大學術典藏 |
2020-05-24T06:00:15Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T02:39:51Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Hsu H.-C.;Tai Y.-J.;Yu-Li Chen;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; Hsu H.-C.; Tai Y.-J.; YU-LI CHEN; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T06:11:34Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; YI-JOU TAI; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-02-04T07:44:50Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; Hsu H.-C.; Tai Y.-J.; Chen Y.-L.; YING-CHENG CHIANG; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-09-27T06:18:43Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 臺大學術典藏 |
2021-03-10T02:34:33Z |
Bevacizumab dose affects the severity of adverse events in gynecologic malignancies
|
Lee S.-P.;Heng-Cheng Hsu;Tai Y.-J.;Chen Y.-L.;Chiang Y.-C.;Chen C.-A.;Cheng W.-F.; Lee S.-P.; HENG-CHENG HSU; Tai Y.-J.; Chen Y.-L.; Chiang Y.-C.; Chen C.-A.; Cheng W.-F. |
| 國立臺灣大學 |
2009 |
Bevacizumab for the Treatment of Corneal Neovascularization
|
陳偉勵; 陳彥名; 朱筱桑; 蔡紫筠; 胡芳蓉; CHEN, WEI-LI; CHEN, YAN-MING; CHU, HSIAO-SANG; TSAI, TZU-YUN; HU, FUNG-RONG |
| 臺大學術典藏 |
2020-10-22T07:41:52Z |
Bevacizumab for the treatment of corneal neovascularization
|
Hu F.-R.; Lin Y.-H.; Tsai T.-Y.; Chu H.-S.; Chen Y.-M.; WEI-LI CHEN |
| 臺大學術典藏 |
2022-07-15T08:17:47Z |
Bevacizumab for the treatment of corneal neovascularization
|
Chen W.-L.; Chen Y.-M.; Chu H.-S.; Lin Y.-H.; Tsai T.-Y.; FUNG-RONG HU |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
|
Chih-Hsin Yang; CHIH-HSIN YANG |
